二甲双胍对2型糖尿病肾病患者长期影响的研究
该回顾性观察性队列研究纳入两家三级医院的10,426例2型糖尿病肾病患者,评估二甲双胍的疗效与安全性。经倾向性评分匹配后,二甲双胍使用与较低的全因死亡率(aHR 0.65;95%CI 0.57-0.73;P<0.001)和终末期肾病进展风险(aHR 0.67;95%CI 0.58-0.77;P<0.001)相关,且未增加乳酸酸中毒风险。作者认为仍需随机对照试验以改变临床实践。
要点
- 在2型糖尿病肾病患者中,二甲双胍使用与较低的全因死亡率和终末期肾病进展风险相关。
- 倾向性评分匹配后,二甲双胍组全因死亡率aHR 0.65(95%CI 0.57-0.73;P<0.001)。
- 二甲双胍未增加全因乳酸酸中毒事件风险(aHR 0.92;95%CI 0.668-1.276;P=0.629)。
核心结论
- 在本回顾性研究中,晚期慢性肾脏病患者(尤其是CKD 3B期)使用二甲双胍可降低全因死亡率和新发终末期肾病风险,且不增加乳酸酸中毒风险。
- 考虑到倾向性评分匹配后仍存在残余偏倚,需要进一步随机对照试验以改变真实世界实践。
研究设计与样本
- 回顾性观察性队列研究,纳入两家三级医院的10,426例2型糖尿病肾病患者。
- 主要结局为全因死亡率和终末期肾病进展,次要结局为二甲双胍相关乳酸酸中毒。
- 采用倾向性评分匹配(PSM)以控制基线特征差异。
主要发现
- 多因素Cox分析显示二甲双胍组全因死亡率和新发终末期肾病较低。
- 倾向性评分匹配后,二甲双胍使用仍与较低的全因死亡率相关(aHR 0.65;95%CI 0.57-0.73;P<0.001)。
- 倾向性评分匹配后,二甲双胍使用仍与较低的终末期肾病进展风险相关(aHR 0.67;95%CI 0.58-0.77;P<0.001)。
- 仅记录到1例二甲双胍相关乳酸酸中毒事件。
- 在原始队列和倾向性评分匹配队列中,二甲双胍使用均未增加全因乳酸酸中毒事件风险(aHR 0.92;95%CI 0.668-1.276;P=0.629)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文指出,即使经过倾向性评分匹配,仍存在残余偏倚。
- 原文结论提出,需要进一步随机对照试验以改变真实世界实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Metformin is the first pharmacological option for treating type 2 diabetes. However, the use of this drug is not recommended in individuals with impaired kidney function because of the perceived risk of lactic acidosis. We aimed to assess the efficacy and safety of metformin in patients with type 2 diabetic kidney disease (DKD). RESEARCH DESIGN AND METHODS: We conducted a retrospective observational cohort study of 10,426 patients with type 2 DKD from two tertiary hospitals. The primary outcomes were all-cause mortality and end-stage renal disease (ESRD) progression. The secondary outcome was metformin-associated lactic acidosis. Taking into account the possibility that patients with less severe disease were prescribed metformin, propensity score matching (PSM) was conducted. RESULTS: All-cause mortality and incident ESRD were lower in the metformin group according to the multivariate Cox analysis. Because the two groups had significantly different baseline characteristics, PSM was performed. After matching, metformin usage was still associated with lower all-cause mortality (adjusted hazard ratio [aHR] 0.65; 95% CI 0.57-0.73; P < 0.001) and ESRD progression (aHR 0.67; 95% CI 0.58-0.77; P < 0.001). Only one event of metformin-associated lactic acidosis was recorded. In both the original and PSM groups, metformin usage did not increase the risk of lactic acidosis events from all causes (aHR 0.92; 95% CI 0.668-1.276; P = 0.629). CONCLUSIONS: In the present retrospective study, metformin usage in advanced chronic kidney disease (CKD) patients, especially those with CKD 3B, decreased the risk of all-cause mortality and incident ESRD. Additionally, metformin did not increase the risk of lactic acidosis. However, considering the remaining biases even after PSM, further randomized controlled trials are needed to change real-world practice.
引用
- Kwon S, Kim YC, Park JY, et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care. 2020. PMID: 32132005. doi:10.2337/dc19-0936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。